| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/03/2000 | WO1999054459A8 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| 02/03/2000 | WO1999051263A3 Methods and modified cells for the treatment of cancer |
| 02/03/2000 | WO1999050251A3 Cyclin dependent kinase inhibitors |
| 02/03/2000 | WO1998055483A9 PYRROLO[2,1,5-cd]INDOLIZINE DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES |
| 02/03/2000 | WO1998050365A9 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents |
| 02/03/2000 | DE19834430A1 Selbstdeletierende Vektoren für die Krebstherapie Selbstdeletierende vectors for cancer therapy |
| 02/03/2000 | DE19833738A1 Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens A method for isolating cancer cells from cell-containing body fluids, and kits for carrying out this method |
| 02/03/2000 | DE19831382A1 Humanes m¶3¶G-cap-spezifisches Kernimportrezeptorprotein mit einer neuen Domänenstruktur, dessen Herstellung und Verwendung Human m¶3¶G-cap-specific nuclear import receptor protein with a new domain tree, its preparation and use |
| 02/03/2000 | CA2338524A1 Inhibitors of urokinase and blood vessel formation |
| 02/03/2000 | CA2338310A1 Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| 02/03/2000 | CA2338305A1 Imidazole compounds |
| 02/03/2000 | CA2338299A1 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 02/03/2000 | CA2338209A1 Biphenyl derivatives |
| 02/03/2000 | CA2338068A1 Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
| 02/03/2000 | CA2337413A1 Substituted phenylamidines,pharmaceutical compositions containing these compounds and processes for preparing them |
| 02/03/2000 | CA2337247A1 Isquinolines as urokinase inhibitors |
| 02/03/2000 | CA2336595A1 Use of prohibitin rna in treatment of cancer |
| 02/03/2000 | CA2335655A1 Keratinocyte derived interferon |
| 02/03/2000 | CA2335653A1 Molecules associated with cell proliferation |
| 02/03/2000 | CA2335646A1 Genes of the dead box protein family, their expression products and use |
| 02/03/2000 | CA2335345A1 Human calcium regulatory proteins |
| 02/03/2000 | CA2335326A1 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| 02/03/2000 | CA2334047A1 Hybrid human/rodent igg antibody to cd3, and methods of its construction |
| 02/02/2000 | EP0975963A1 Prostate specific antigen substrates |
| 02/02/2000 | EP0975780A2 Il-2 gene expression and delivery systems and uses |
| 02/02/2000 | EP0975772A1 Reagents and methods useful for detecting diseases of the gastrointestinal tract |
| 02/02/2000 | EP0975769A1 Novel prostate-associated kallikrein |
| 02/02/2000 | EP0975764A1 A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
| 02/02/2000 | EP0975759A1 Human tumor-associated kazal inhibitor |
| 02/02/2000 | EP0975758A1 POLYPEPTIDE HAVING A GTPase REGULATOR ACTIVITY, NUCLEIC ACIDS CODING THEREFOR AND THEIR USE IN DIAGNOSTICS AND THERAPY |
| 02/02/2000 | EP0975751A1 A tm4sf human tumor-associated antigen |
| 02/02/2000 | EP0975750A2 Modified retinoblastoma tumor suppressor proteins |
| 02/02/2000 | EP0975743A1 Inhibitors for urokinase receptor |
| 02/02/2000 | EP0975680A1 Interactive system for substance presentation and elimination |
| 02/02/2000 | EP0975674A1 Immunotoxins, comprising an onc protein, directed against malignant cells |
| 02/02/2000 | EP0975670A1 Radiolabelled somatostatin receptor ligands for diagnosis and therapy |
| 02/02/2000 | EP0975669A1 Calcitonin receptor-binding peptides |
| 02/02/2000 | EP0975668A1 MODIFIED TNF$g(a) MOLECULES, DNA ENCODING SUCH MODIFIED TNF$g(a) MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNF$g(a) MOLECULES AND DNA |
| 02/02/2000 | EP0975666A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 02/02/2000 | EP0975665A1 Active substance and composition inhibiting tumorous proliferation in ectoderm derived tissues |
| 02/02/2000 | EP0975661A1 The proliferation of cell-inhibiting peptide and its use |
| 02/02/2000 | EP0975651A1 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease |
| 02/02/2000 | EP0975649A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
| 02/02/2000 | EP0975640A1 Vinca alkaloid antimitotic halogenated derivatives |
| 02/02/2000 | EP0975637A2 Amidino-camptothecin derivatives |
| 02/02/2000 | EP0975632A1 Alkaloid halide salts of swainsonine and methods of use |
| 02/02/2000 | EP0975629A1 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators |
| 02/02/2000 | EP0975628A1 Prevention of breast cancer with selective estrogen receptor modulators |
| 02/02/2000 | EP0975610A1 Tripeptide and tetrapeptide pharmaceutical compounds |
| 02/02/2000 | EP0975606A1 Crambescidin compounds |
| 02/02/2000 | EP0975592A1 Benzyloxy prodigiosine compounds |
| 02/02/2000 | EP0975573A1 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| 02/02/2000 | EP0975361A1 Methods of modulating immune coagulation |
| 02/02/2000 | EP0975354A1 Ligand/lytic peptide compositions and methods of use |
| 02/02/2000 | EP0975350A1 Use of an extract of alchemilli vulgaris |
| 02/02/2000 | EP0975346A1 Pharmaceutical, cosmetic and/or food composition with antioxidant properties |
| 02/02/2000 | EP0975341A1 Synergistic antitumor composition containing a naphthalensulphonic acid derivative |
| 02/02/2000 | EP0975338A2 2,2'-bi-1h-pyrrole derivatives useful in the treatment of leukemia brought on by htlv-i |
| 02/02/2000 | EP0975329A1 Lipid complexes and liposomes of highly insoluble platinum complexes |
| 02/02/2000 | EP0975225A1 Fibrocyte-based cellular therapy formulations |
| 02/02/2000 | EP0975218A1 Nucleophile substituted ecteinascidins and n-oxide ecteinascidins |
| 02/02/2000 | EP0839205B1 Liver-specific adenovirus expression vector |
| 02/02/2000 | EP0767794B1 Phosphinic acid derivatives |
| 02/02/2000 | EP0648126B1 Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma, stomach cancer and breast cancer |
| 02/02/2000 | EP0584136B1 Determination of motifs of peptides on mhc molecules |
| 02/02/2000 | CN1243544A Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons |
| 02/02/2000 | CN1243507A Bis-sulfonomides hydroxamic acids as MMP inhibitors |
| 02/02/2000 | CN1243445A Photochemotherapeutic compositions |
| 02/02/2000 | CN1243444A Modified tumor necrosis factor |
| 02/02/2000 | CN1243128A Semisynthesizing method for 20(S)-ginsenoside Rg3, and use in medicine |
| 02/02/2000 | CN1243125A Polyglutaminic acid or sodium polyglutamate taxinine A ester compound and use thereof |
| 02/02/2000 | CN1048983C Preparation of new initiator of taxane derivative and its use |
| 02/01/2000 | US6020513 Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods |
| 02/01/2000 | US6020478 Human tumor-associated antigen |
| 02/01/2000 | US6020473 Nucleic acids encoding variants of vascular endothelial cell growth factor |
| 02/01/2000 | US6020466 Myeloid cell leukemia associated gene mcl-1 |
| 02/01/2000 | US6020372 Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders |
| 02/01/2000 | US6020358 Substituted phenethylsulfones and method of reducing TNFα levels |
| 02/01/2000 | US6020351 Carotenoid-nicotinamide-zinc compositions and methods of treatment using same |
| 02/01/2000 | US6020326 Method for inhibition of bone growth by anionic polymers |
| 02/01/2000 | US6020320 Acyl deoxyribonucleoside derivatives and uses thereof |
| 02/01/2000 | US6020315 Preparation having increased in vivo tolerability |
| 02/01/2000 | US6020308 Methods for improving therapeutic effectiveness of treatment of vascularization disorders |
| 02/01/2000 | US6020306 Receptor-type tyrosine kinase and use thereof |
| 02/01/2000 | US6020189 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 02/01/2000 | US6020179 Nucleic acids encoding human tyrosine phosphatases |
| 02/01/2000 | US6020172 Nucleic acid delivery with ovine adenoviral vectors |
| 02/01/2000 | US6020164 Human RNA binding proteins |
| 02/01/2000 | US6020157 Polynucleotides encoding HFGAN72X receptor |
| 02/01/2000 | US6020152 Lymphocyte-associated cell surface protein |
| 02/01/2000 | US6019987 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
| 02/01/2000 | CA2173387C A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation |
| 02/01/2000 | CA2105492C Glutathione analogs and paralog panels comprising glutathione mimics |
| 01/30/2000 | CA2244554A1 Inhibition of graft versus host disease |
| 01/27/2000 | WO2000004194A1 Gene sequence variances with utility in determining the treatment of disease |
| 01/27/2000 | WO2000004150A1 Human presenilin-associated protein |
| 01/27/2000 | WO2000004149A2 Compositions and methods for therapy and diagnosis of prostate cancer |
| 01/27/2000 | WO2000004144A1 Snurpotine i human m3g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 01/27/2000 | WO2000004137A1 Human aspartic proteases |
| 01/27/2000 | WO2000004052A2 Soluble derivatives of anti-angiogenic peptides |